Lumena Pharmaceuticals Takes $23M To Fight Rare Liver Disease
This article was originally published in The Pink Sheet Daily
The San Diego start-up will use its Series A round to continue development on a pair of drugs for cholestatic liver disease. Once studied by Pfizer and Sanofi to fight high cholesterol but shelved years ago as statins proved more effective, the drugs show promise in orphan indications.
You may also be interested in...
Biotech investment momentum may have slowed recently, but the San Diego biotech is hoping the IPO window remains open. The company is developing a compound shelved by Pfizer to address high cholesterol; LUM001 currently is in Phase II for a set of cholestatic liver diseases.
Q2 2013 biopharma financing increased 139% to $11 billion over Q1’s $4.6 billion, thanks mostly to two huge transactions by Valeant to fund its $8.7 billion takeover of ophthalmics player Bausch & Lomb, the company’s largest acquisition to date. Options and antibody-drug conjugates featured prominently in the alliances.
Using technology spun out of UCSF, a new company hopes to develop oncology drugs that target effector mechanisms of protein synthesis, thereby affecting multiple oncogenes simultaneously. The San Diego-based biotech also hopes to license out its platform for non-cancer indications, bringing in non-dilutive money.